vs

Side-by-side financial comparison of Fabrinet (FN) and GLOBUS MEDICAL INC (GMED). Click either name above to swap in a different company.

Fabrinet is the larger business by last-quarter revenue ($1.1B vs $826.4M, roughly 1.4× GLOBUS MEDICAL INC). GLOBUS MEDICAL INC runs the higher net margin — 17.0% vs 9.9%, a 7.1% gap on every dollar of revenue. On growth, Fabrinet posted the faster year-over-year revenue change (35.9% vs 25.7%). GLOBUS MEDICAL INC produced more free cash flow last quarter ($202.4M vs $-5.3M). Over the past eight quarters, Fabrinet's revenue compounded faster (24.4% CAGR vs 16.7%).

Below is a list of companies having stocks that are included in the S&P MidCap 400 stock market index. The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 400 mid-cap, mostly American, companies. Although called the S&P 400, the index sometimes contains more than 400 stocks when it includes two or more share classes of stock from one of its component companies.

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

FN vs GMED — Head-to-Head

Bigger by revenue
FN
FN
1.4× larger
FN
$1.1B
$826.4M
GMED
Growing faster (revenue YoY)
FN
FN
+10.2% gap
FN
35.9%
25.7%
GMED
Higher net margin
GMED
GMED
7.1% more per $
GMED
17.0%
9.9%
FN
More free cash flow
GMED
GMED
$207.7M more FCF
GMED
$202.4M
$-5.3M
FN
Faster 2-yr revenue CAGR
FN
FN
Annualised
FN
24.4%
16.7%
GMED

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
FN
FN
GMED
GMED
Revenue
$1.1B
$826.4M
Net Profit
$112.6M
$140.6M
Gross Margin
12.2%
68.4%
Operating Margin
10.1%
20.5%
Net Margin
9.9%
17.0%
Revenue YoY
35.9%
25.7%
Net Profit YoY
30.0%
430.4%
EPS (diluted)
$3.11
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FN
FN
GMED
GMED
Q4 25
$1.1B
$826.4M
Q3 25
$978.1M
$769.0M
Q2 25
$909.7M
$745.3M
Q1 25
$871.8M
$598.1M
Q4 24
$833.6M
$657.3M
Q3 24
$804.2M
$625.7M
Q2 24
$753.3M
$629.7M
Q1 24
$731.5M
$606.7M
Net Profit
FN
FN
GMED
GMED
Q4 25
$112.6M
$140.6M
Q3 25
$95.9M
$119.0M
Q2 25
$87.2M
$202.8M
Q1 25
$81.3M
$75.5M
Q4 24
$86.6M
$26.5M
Q3 24
$77.4M
$51.8M
Q2 24
$81.1M
$31.8M
Q1 24
$80.9M
$-7.1M
Gross Margin
FN
FN
GMED
GMED
Q4 25
12.2%
68.4%
Q3 25
11.9%
67.2%
Q2 25
12.2%
66.6%
Q1 25
11.7%
67.3%
Q4 24
12.1%
59.9%
Q3 24
12.3%
56.8%
Q2 24
12.3%
58.7%
Q1 24
12.4%
60.2%
Operating Margin
FN
FN
GMED
GMED
Q4 25
10.1%
20.5%
Q3 25
9.6%
17.9%
Q2 25
9.8%
10.2%
Q1 25
9.0%
16.2%
Q4 24
9.5%
9.2%
Q3 24
9.6%
7.7%
Q2 24
9.7%
7.9%
Q1 24
9.7%
1.3%
Net Margin
FN
FN
GMED
GMED
Q4 25
9.9%
17.0%
Q3 25
9.8%
15.5%
Q2 25
9.6%
27.2%
Q1 25
9.3%
12.6%
Q4 24
10.4%
4.0%
Q3 24
9.6%
8.3%
Q2 24
10.8%
5.0%
Q1 24
11.1%
-1.2%
EPS (diluted)
FN
FN
GMED
GMED
Q4 25
$3.11
$1.01
Q3 25
$2.66
$0.88
Q2 25
$2.41
$1.49
Q1 25
$2.25
$0.54
Q4 24
$2.38
$0.19
Q3 24
$2.13
$0.38
Q2 24
$2.22
$0.23
Q1 24
$2.21
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FN
FN
GMED
GMED
Cash + ST InvestmentsLiquidity on hand
$960.8M
$557.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.2B
$4.6B
Total Assets
$3.3B
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FN
FN
GMED
GMED
Q4 25
$960.8M
$557.2M
Q3 25
$968.8M
$18.8M
Q2 25
$934.2M
Q1 25
$950.7M
Q4 24
$934.6M
$890.1M
Q3 24
$908.9M
$71.9M
Q2 24
$858.6M
$82.5M
Q1 24
$794.0M
$80.4M
Stockholders' Equity
FN
FN
GMED
GMED
Q4 25
$2.2B
$4.6B
Q3 25
$2.1B
$4.4B
Q2 25
$2.0B
$4.3B
Q1 25
$1.9B
$4.1B
Q4 24
$1.8B
$4.2B
Q3 24
$1.8B
$4.1B
Q2 24
$1.7B
$4.0B
Q1 24
$1.7B
$3.9B
Total Assets
FN
FN
GMED
GMED
Q4 25
$3.3B
$5.3B
Q3 25
$3.0B
$5.1B
Q2 25
$2.8B
$5.0B
Q1 25
$2.6B
$4.7B
Q4 24
$2.5B
$5.3B
Q3 24
$2.4B
$5.1B
Q2 24
$2.3B
$5.0B
Q1 24
$2.2B
$4.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FN
FN
GMED
GMED
Operating Cash FlowLast quarter
$46.3M
$248.6M
Free Cash FlowOCF − Capex
$-5.3M
$202.4M
FCF MarginFCF / Revenue
-0.5%
24.5%
Capex IntensityCapex / Revenue
4.6%
5.6%
Cash ConversionOCF / Net Profit
0.41×
1.77×
TTM Free Cash FlowTrailing 4 quarters
$102.3M
$588.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FN
FN
GMED
GMED
Q4 25
$46.3M
$248.6M
Q3 25
$102.6M
$249.7M
Q2 25
$55.1M
$77.9M
Q1 25
$74.2M
$177.3M
Q4 24
$115.9M
$210.3M
Q3 24
$83.2M
$203.7M
Q2 24
$83.1M
$54.3M
Q1 24
$100.9M
$52.4M
Free Cash Flow
FN
FN
GMED
GMED
Q4 25
$-5.3M
$202.4M
Q3 25
$57.3M
$213.9M
Q2 25
$4.7M
$31.3M
Q1 25
$45.7M
$141.2M
Q4 24
$94.0M
$193.2M
Q3 24
$62.9M
$161.7M
Q2 24
$70.4M
$26.5M
Q1 24
$87.3M
$23.8M
FCF Margin
FN
FN
GMED
GMED
Q4 25
-0.5%
24.5%
Q3 25
5.9%
27.8%
Q2 25
0.5%
4.2%
Q1 25
5.2%
23.6%
Q4 24
11.3%
29.4%
Q3 24
7.8%
25.8%
Q2 24
9.3%
4.2%
Q1 24
11.9%
3.9%
Capex Intensity
FN
FN
GMED
GMED
Q4 25
4.6%
5.6%
Q3 25
4.6%
4.7%
Q2 25
5.5%
6.2%
Q1 25
3.3%
6.0%
Q4 24
2.6%
2.6%
Q3 24
2.5%
6.7%
Q2 24
1.7%
4.4%
Q1 24
1.9%
4.7%
Cash Conversion
FN
FN
GMED
GMED
Q4 25
0.41×
1.77×
Q3 25
1.07×
2.10×
Q2 25
0.63×
0.38×
Q1 25
0.91×
2.35×
Q4 24
1.34×
7.94×
Q3 24
1.07×
3.93×
Q2 24
1.02×
1.71×
Q1 24
1.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FN
FN

Optical Communications$832.6M73%
Non Optical Communications$300.3M27%

GMED
GMED

Other$391.8M47%
Nevro Merger Agreement$293.6M36%
Enabling Technologies$141.0M17%

Related Comparisons